Background {#Sec1}
==========

The Centers for Disease Control and Prevention considers *Acinetobacter baumannii* (AB) a "serious" threat \[[@CR1]\]. AB's resistance mechanisms target both first-line and salvage broad-spectrum agents, with approximate doubling in carbapenem and multidrug resistance (MDR) in the United States over the last decade \[[@CR2], [@CR3]\]. In addition to its public health implications, the rising tide of drug resistance presents a difficult clinical conundrum. In serious infections, appropriate initial therapy determines clinical outcomes. However, more extensive drug resistance makes it a challenge to select appropriate treatment \[[@CR4]--[@CR13]\]. Carbapenem resistance among AB in severe sepsis and/or septic shock increases the risk of receiving inappropriate empiric therapy (IET) nearly threefold, raising the risk of death \[[@CR14]\]. Unfortunately, using carbapenems as empiric therapy in hopes of minimizing IET drives increasing carbapenem resistance. Because of the limited data on this issue in AB, we conducted a multicenter, retrospective cohort study to explore the impact of MDR in IET and of IET on hospital mortality in AB.

Methods {#Sec2}
=======

We conducted a multicenter retrospective cohort study of patients admitted to the hospital with pneumonia and/or sepsis and included in the Premier Research database in the 2009--2013. We hypothesized that multidrug-resistant AB (MDR-AB) (primary exposure) increases the risk of receiving IET (primary outcome), and that IET increases hospital mortality. Because this study used already-existing, Health Insurance Portability and Accountability Act ("HIPAA")-compliant, fully de-identified data, it was exempt from institutional review board (IRB) review.

Patient population {#Sec3}
------------------

Patients were included if they were adults (aged ≥ 18 years) hospitalized with pneumonia and/or sepsis. Pneumonia was identified by the principal diagnosis International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 481--486, or by respiratory failure codes (518.81 or 518.84) with pneumonia as a secondary diagnosis. Sepsis was identified by the principal diagnosis codes 038, 038.9, 020.0, 790.7, 995.92, or 785.52, or by respiratory failure codes (518.81 or 518.84) with sepsis as a secondary diagnosis \[[@CR15]--[@CR18]\]. Only patients with community-onset (present on admission) infection and antibiotic treatment beginning within the first 2 hospital days and continued for at least three consecutive days or until discharge were included \[[@CR15]--[@CR17]\]. Patients were excluded if they had been transferred from another acute care facility, had cystic fibrosis, or had a hospital length of stay of 1 day or less. Those with both pneumonia and sepsis were included in the pneumonia group. Patients were followed until death in or discharge from the hospital. Only patients with a positive AB culture from a pulmonary or blood source who met the above criteria were included in the analysis.

Data source {#Sec4}
-----------

The Premier Research database, an electronic laboratory, pharmacy, and billing data repository for 2009--2013, contains approximately 15 % of all U.S. hospitalizations nationwide. In addition to patient age, sex, race and/or ethnicity, principal and secondary diagnoses, and procedures, the database contains a date-stamped log of all medications, laboratory tests, and diagnostic and therapeutic services charged to the patient or the patient's insurer. We used data from 176 U.S. institutions that submit microbiological data into the database. Eligible time began only following the commencement of microbiological data submission by each institution.

Baseline variables {#Sec5}
------------------

We classified infection (pneumonia or sepsis) as healthcare-associated (HCA) if one or more of the following were present: (1) prior hospitalization within 90 days of the index hospitalization, (2) hemodialysis, (3) admission from a long-term care facility, and/or (4) immune suppression. All other infections were considered community-acquired (CA). Patient-level factors included demographic variables and comorbid conditions. Charlson comorbidity index score was computed as a measure of the burden of chronic illness, while intensive care unit (ICU) admission, mechanical ventilation, and vasopressor use served as markers for disease severity. Hospital-level characteristics examined were geographic region, size, teaching status, and urbanicity.

Microbiological and treatment-related variables and definitions {#Sec6}
---------------------------------------------------------------

Blood and respiratory cultures had to be obtained within the first 2 days of hospitalization. AB isolates were classified as S (susceptible), I (intermediate), or R (resistant). For the purposes of the present analyses, I and R were grouped together as nonsusceptible. MDR-AB was defined, per Magiorakos et al., as any AB resistant to at least one agent in at least three antimicrobial classes \[[@CR19]\]. Similarly, extensively drug resistant AB (XDR-AB) was defined as an AB resistant to at least one agent in all but two or fewer classes listed above, and pandrug-resistant AB (PDR-AB) as an AB resistant to all antimicrobial agents listed above \[[@CR19]\].

IET was present if the antibiotic administered did not cover the organism or if coverage did not start within 2 days of obtaining the positive culture. Because the role of combination therapy in treating AB is not well defined, combination therapy was not included in the definition of IET \[[@CR20]\]. IET was deemed "indeterminate" if the susceptibility of AB to the regimen received was not reported. These cases were excluded from the IET analysis. All microbiological testing was performed at the institutions contributing data to the database and conformed to the Clinical & Laboratory Standards Institute standards.

Statistical analyses {#Sec7}
--------------------

We compared characteristics of patients infected with MDR-AB with those of patients with non-MDR-AB infection, as well as characteristics of patients who received IET with those of patients treated with non-IET. Continuous variables were reported as means with SD when distributed normally or as medians with 25th and 75th percentiles when skewed. Differences between mean values were tested via Student's *t* test, and differences between medians were assessed using the Mann-Whitney *U* test. Categorical data were summarized as proportions, and chi-square test or Fisher's exact test (when cell counts were ≤4) was used to examine differences between groups.

We developed a generalized logistic regression model to explore the relationship between MDR-AB and the risk of IET. Covariates in the model included demographics (sex, age, whether the infection was HCA), Elixhauser comorbidities, and measures of illness severity by hospital day 2. We calculated the relative risk ratio with 95 % CI of receiving IET for MDR-AB vs. non-MDR-AB, based on Huber-White robust standard errors clustered at the hospital level \[[@CR21]\]. To confirm our results, we created two other models: (1) a nonparse model that included all of the predictors in the generalized logistic regression model with a large number of additional treatments present or absent by hospital day 2, and (2) a propensity-matched model with propensity for MDR-AB derived from a logistic regression model using the nonparse model's predictors, and MDR-AB matched to non-MDR-AB patients using a 5:1 Greedy algorithm \[[@CR22], [@CR23]\].

All tests were two-tailed, and a *p* value \< 0.05 was deemed a priori to represent statistical significance. All analyses were performed in Stata/MP 13.1 for Windows software (StataCorp LP, College Station, TX, USA).

Results {#Sec8}
=======

Among the 229,028 enrolled patients with pneumonia or sepsis, 1423 (0.6 %) had a pulmonary or blood culture positive for AB, of which 1171 (82.3 %) were MDR, 239 (16.8 %) were XDR, and 0 (0.0 %) were PDR. Patients with MDR-AB were older (63.7 ± 15.4 vs. 61.0 ± 16.9 years, *p* = 0.014) than those with non-MDR-AB, while the racial distributions were comparable in both groups (Table [1](#Tab1){ref-type="table"}). Although the distribution of some chronic conditions varied, there was no difference between the groups in the Charlson comorbidity index (Table [1](#Tab1){ref-type="table"}). MDR-AB was more common than non-MDR-AB in the West and the Midwest, in urban hospitals, and in hospitals of medium size (200--499 beds). Both large hospitals (500+ beds) and those with an academic program were less likely to have MDR-AB than non-MDR-AB (Table [1](#Tab1){ref-type="table"}).Table 1Baseline characteristicsNon-MDR-AB (*n* = 252)%MDR-AB (*n* = 1171)%*p* ValueMean age, years (SD)61.0 (16.9)63.7 (15.4)0.014Male sex13453.2 %63354.1 %0.799Race/ethnicity White13453.2 %63354.1 %\< 0.001 Black Hispanic15963.1 %73863.0 % Other5521.8 %27623.6 %Admission source Non-healthcare facility (including from home)16766.3 %57348.9 %\< 0.001 Clinic145.6 %262.2 % Transfer from ECF135.2 %28023.9 % Transfer from another non-acute care facility31.2 %453.8 % Emergency department5421.4 %23620.2 % Other10.4 %111.0 %Elixhauser comorbidities Congestive heart failure6124.2 %35330.1 %0.060 Valvular disease218.3 %927.9 %0.800 Pulmonary circulation disease166.3 %1079.1 %0.153 Peripheral vascular disease3313.1 %14512.4 %0.756 Paralysis3212.7 %29224.9 %\<0.001 Other neurological disorders4417.5 %30025.6 %0.006 Chronic pulmonary disease10842.9 %50743.3 %0.898 Diabetes without chronic complications6525.8 %39033.3 %0.020 Diabetes with chronic complications218.3 %968.2 %0.943 Hypothyroidism2811.1 %18215.5 %0.072 Renal failure6626.2 %35930.7 %0.160 Liver disease176.7 %373.2 %0.007 Peptic ulcer disease with bleeding00.0 %00.0 %1.000 AIDS00.0 %00.0 %1.000 Lymphoma10.4 %161.4 %0.336 Metastatic cancer207.9 %302.6 %\< 0.001 Solid tumor without metastasis176.7 %312.6 %0.001 Rheumatoid arthritis/collagen vascular52.0 %463.9 %0.132 Coagulopathy4517.9 %13411.4 %0.005 Obesity4116.3 %19116.3 %0.987 Weight loss4919.4 %39233.5 %\< 0.001 Fluid and electrolyte disorders14557.5 %62853.6 %0.258 Chronic blood loss anemia52.0 %161.4 %0.461 Deficiency anemia9738.5 %59350.6 %\< 0.001 Alcohol abuse228.7 %353.0 %\< 0.001 Drug abuse166.3 %292.5 %0.001 Psychosis135.2 %776.6 %0.402 Depression2911.5 %16113.7 %0.343 Hypertension15862.7 %66957.1 %0.104Charlson comorbidity index score 05823.0 %24721.1 %0.542 16023.8 %29825.4 % 25019.8 %24420.8 % 33513.9 %17915.3 % 4218.3 %1129.6 % 5+2811.1 %917.8 % Mean (SD)2.2 (2.4)2.0 (1.9)0.096 Median \[IQR\]2 \[1--3\]2 \[1--3\]0.873Hospital characteristics U.S. census region  Midwest4919.4 %37732.2 %\< 0.001  Northeast5421.4 %16414.0 %  South12248.4 %43637.2 %  West2710.7 %19416.6 % Number of beds   \< 2002610.3 %14012.0 %0.007  200--2994919.4 %27223.2 %  300--4998433.3 %45438.8 %  500+9336.9 %30526.0 % Teaching13754.4 %53745.9 %0.014 Urban23392.5 %113596.9 %0.001*MDR-AB* multidrug-resistant *Acinetobacter baumannii*, *ECF* extended care facility

In both groups (MDR-AB and non-MDR-AB), the majority (approximately three-fourths) of the patients had a diagnosis of sepsis, with the remaining one-fourth having pneumonia (Table [2](#Tab2){ref-type="table"}). Patients harboring MDR-AB were more likely to have an HCA infection (64.9 % vs. 42.5 %, *p* \< 0.001) along with higher illness severity by day 2 of admission (ICU 68.0 % vs. 59.5 %, *p* \< 0.001; mechanical ventilation 56.2 % vs. 42.1 %, *p* \< 0.001; vasopressors 15.5 % vs. 17.6 %, *p* = 0.420) than non-MDR-AB patients (Table [2](#Tab2){ref-type="table"}). Although patients in the MDR-AB group had a higher prevalence of use of antipseudomonal carbapenems, aminoglycosides, and polymyxins than those in the non-MDR-AB group, they were also far more likely to receive IET (76.2 % MDR-AB vs. 13.8 % non-MDR-AB, *p* \< 0.001), regardless of infection type (Fig. [1](#Fig1){ref-type="fig"}). Unadjusted hospital mortality among patients with MDR-AB was nearly double that in those with non-MDR-AB (23.7 % vs. 12.7 %, *p* \< 0.001).Table 2Infection characteristics and treatmentNon-MDR-AB (*n* = 252)%MDR-AB (*n* = 1171)%*p* ValueInfection characteristics Sepsis18473.0 %87574.7 %0.573 Pneumonia6827.0 %29625.3 % HCA10742.5 %76064.9 %\< 0.001Illness severity measures by day 2 ICU admission15059.5 %79668.0 %0.010 Mechanical ventilation10642.1 %65856.2 %\< 0.001 Vasopressors3915.5 %20617.6 %0.420Antibiotics administered by day 2 Antipseudomonal penicillins with β-lactamase inhibitor14055.6 %58850.2 %0.124 Extended-spectrum cephalosporins10039.7 %37331.9 %0.017 Antipseudomonal fluoroquinolones9638.1 %48941.8 %0.284 Antipseudomonal carbapenems3714.7 %35029.9 %\< 0.001 Aminoglycosides259.9 %20417.4 %0.003 Penicillins with β-lactamase inhibitors41.6 %191.6 %1.000 Tetracyclines31.2 %60.5 %0.203 Folate pathway inhibitors31.2 %110.9 %0.724 Polymyxins00.0 %373.2 %0.001Empiric treatment appropriateness Non-IET16264.3 %21718.5 %\< 0.001 IET2610.3 %69359.2 % Indeterminate6425.4 %26122.3 %*Abbreviations: MDR-AB* multidrug-resistant *Acinetobacter baumannii*, *HCA* healthcare-associated, *ICU* intensive care unit, *IET* inappropriate empiric therapyFig. 1Inappropriate empiric therapy as a function of multidrug resistance (MDR). *HCA* healthcare-associated

When we compared the cohort of 1098 patients (77.2 % of all AB patients) with valid, known antimicrobial treatment data based on the receipt of IET, we found that only 379 (34.5 %) received appropriate therapy (Table [3](#Tab3){ref-type="table"}). The rate of sepsis upon admission did not significantly differ between IET and non-IET patients (Table [3](#Tab3){ref-type="table"}). Unadjusted hospital mortality was higher in patients receiving IET than non-IET (23.6 % vs. 16.6 %, *p* = 0.007) in all infection types (Fig. [2](#Fig2){ref-type="fig"}).Table 3Characteristics of the cohort, based on receipt of inappropriate empiric therapyNon-IET (*n* = 379)%IET (*n* = 719)%*p* ValueBaseline characteristics Mean age, years (SD)62.4 (15.6)62.7 (15.9)0.767 Male sex20253.3 %37351.9 %0.654 Race/ethnicity  White23662.3 %46464.5 %0.055  Black10327.2 %15922.1 %  Hispanic71.8 %324.5 %  Other338.7 %648.9 % Admission source  Non-healthcare facility (including from home)22358.8 %35749.7 %0.022  Clinic143.7 %152.1 %  Transfer from ECF6918.2 %17324.1 %  Transfer from another non-acute care facility82.1 %202.8 %  Emergency department6316.6 %14820.6 %  Other20.5 %60.9 % Elixhauser comorbidities  Congestive heart failure9721.5 %20930.4 %0.222  Valvular disease306.6 %537.7 %0.746  Pulmonary circulation disease265.8 %629.0 %0.306  Peripheral vascular disease5111.3 %8211.9 %0.322  Paralysis8518.8 %17625.6 %0.448  Other neurological disorders8218.1 %18526.9 %0.133  Chronic pulmonary disease16436.3 %30544.4 %0.786  Diabetes without chronic complications10523.2 %24135.1 %0.049  Diabetes with chronic complications388.4 %568.2 %0.208  Hypothyroidism4910.8 %11917.3 %0.113  Renal failure10723.7 %21731.6 %0.501  Liver disease173.8 %273.9 %0.557  Peptic ulcer disease with bleeding00.0 %00.0 %1.000  AIDS00.0 %00.0 %1.000  Lymphoma20.4 %101.5 %0.236  Metastatic cancer245.3 %172.5 %0.001  Solid tumor without metastasis184.0 %192.8 %0.066  Rheumatoid arthritis/collagen vascular112.4 %294.2 %0.342  Coagulopathy5812.8 %8312.1 %0.077  Obesity4810.6 %12818.6 %0.027  Weight loss9420.8 %25036.4 %0.001  Fluid and electrolyte disorders21948.5 %39357.2 %0.322  Chronic blood loss anemia51.1 %91.3 %0.924  Deficiency anemia17338.3 %36352.8 %0.127  Alcohol abuse184.0 %243.5 %0.246  Drug abuse163.5 %192.8 %0.157  Psychosis224.9 %456.6 %0.765  Depression5011.1 %9614.0 %0.941  Hypertension21547.6 %41360.1 %0.821 Charlson comorbidity score  07219.0 %16422.8 %0.152  110828.5 %17724.6 %  26416.9 %15121.0 %  36216.4 %10815.0 %  4349.0 %669.2 %  5+3910.3 %537.4 %  Mean (SD)2.2 (2.2)2.0 (1.9)0.043  Median \[IQR\]2 \[1--3\]2 \[1--3\]0.202Infection characteristics and treatments Infection characteristics  Sepsis29678.1 %52573.0 %0.065  Pneumonia8321.9 %19427.0 %  HCA22258.6 %46464.5 %0.053  MDR-AB21757.3 %69396.4 %\< 0.001 Illness severity  ICU admission24965.7 %48267.0 %0.655  Mechanical ventilation20654.4 %39054.2 %0.972  Vasopressors6416.9 %12116.8 %0.981 Antibiotics administered  Antipseudomonal penicillins with β-lactamase inhibitor9124.0 %12317.1 %0.006  Antipseudomonal fluoroquinolones9725.6 %20929.1 %0.222  Extended-spectrum cephalosporins17746.7 %33947.1 %0.888  Antipseudomonal carbapenems19050.1 %35048.7 %0.647  Aminoglycosides14036.9 %26937.4 %0.877  Penicillins with β-lactamase inhibitors51.3 %91.3 %0.924  Polymyxins123.2 %91.3 %0.028  Folate pathway inhibitors71.8 %233.2 %0.191  Tetracyclines10.3 %40.6 %0.665Hospital characteristics U.S. region  Midwest11831.1 %23432.5 %\< 0.001  Northeast6015.8 %9112.7 %  South16744.1 %25435.3 %  West349.0 %14019.5 % Number of beds   \< 2004110.8 %7810.8 %0.011  200--2996517.2 %16522.9 %  300--49914337.7 %29240.6 %  500+13034.3 %18425.6 % Teaching21255.9 %29240.6 %\< 0.001 Urban35794.2 %69696.8 %0.038 Hospital mortality6316.6 %17023.6 %0.007*Abbreviations: IET* inappropriate empiric therapy, *ECF* extended care facility, *HCA* healthcare-associated, *MDR-AB* multidrug-resistant *Acinetobacter baumannii*, *ICU* intensive care unitFig. 2Mortality and inappropriate empiric therapy. *HCA* healthcare-associated

In a regression model designed to explore the impact of MDR on the risk of IET exposure, MDR-AB was the single strongest predictor of receiving IET (adjusted relative risk ratio 5.5, 95 % CI 4.0--7.7, *p* \< 0.001) (Table [4](#Tab4){ref-type="table"}). The confirmatory analyses produced similar risk ratios (Table [4](#Tab4){ref-type="table"}).Table 4Adjusted risk of inappropriate empiric therapy and hospital mortalityRisk of IET in the setting of MDR-ABMarginal effect, IET in non-MDR-ABMarginal effect, IET in MDR-ABAdjusted relative risk ratio (95 % CI)*p* ValueMethod Parse model13.8 %76.2 %5.5 (4.0--7.7)\< 0.001 Propensity score (based on 204 matched pairs; 81.0 % matched)13.4 %73.9 %5.5 (3.6--8.4)\< 0.001 Nonparse model14.4 %75.6 %5.3 (3.7--7.4)\< 0.001Risk of death in the setting of IETMarginal effect, mortality in non-IETMarginal effect, mortality in IETAdjusted relative risk ratio (95 % CI)*p* ValueMethod Parse model15.9 %24.3 %1.53 (1.21--1.93)\< 0.001 Propensity score (based on 226 matched pairs; 59.6 % matched)15.0 %27.8 %1.85 (1.35--2.54)\< 0.001 Nonparse model14.5 %25.6 %1.76 (1.36--2.28)\< 0.001*IET* inappropriate empiric therapy, *MDR-AB* multidrug-resistant *Acinetobacter baumannii*

In a nonparse generalized regression model adjusting for all confounders (demographics, comorbidities, severity of illness measures, hospital characteristics), IET was associated with an increased risk of in-hospital mortality (adjusted relative risk ratio 1.76; 95 % CI 1.36--2.28, *p* \< 0.001 (Table [4](#Tab4){ref-type="table"}). The parse model and propensity-matched analysis produced similar risk ratios.

Discussion {#Sec9}
==========

In this large, multicenter cohort study, we have demonstrated that CA and HCA pneumonia and sepsis are rarely caused by AB. However, when AB is present, it is most often MDR. Moreover, harboring MDR puts patients at a fivefold increased risk of receiving IET, which is in turn associated with increased hospital mortality.

Multiple investigators have documented the exceedingly high and rising rate of AB resistance. In a multicenter microbiology database study in the United States, we noted a rise in MDR-AB from 21.4 % between 2003 and 2005 to 35.2 % in the 2009--2012 period \[[@CR3]\]. Similarly, the Center for Disease Dynamics, Economics & Policy (CDDEP) reported an MDR-AB increase from 32.1 % in 2009 to 51.0 % in 2010 \[[@CR2]\]. The discrepancy between the two studies reflects the populations evaluated and the definitions of MDR applied. While our prior investigation was limited to only patients with severe sepsis and septic shock, the CDDEP surveillance included all infection sources. Additionally, we limited drug definitions to those where clinical efficacy data were available, while CDDEP included all pertinent drug categories.

Our present study, though not longitudinal, confirms the high probability of MDR-AB, though the rate is higher than that in either of the surveillance studies. Although the our examined population is more similar to that in our previous surveillance study than to the CDDEP surveillance, the IET definition is more in line with that of the CDDEP \[[@CR19]\]. Because our data represent years 2009--2013, the high prevalence may simply be consistent with continued growth of this resistant pathogen beyond the time frame examined in either of the previous surveillance efforts.

We confirm that antimicrobial resistance confers a high risk for IET. A previous single-center study reported that having severe sepsis or septic shock caused by carbapenem-resistant AB doubled the risk of IET \[[@CR14]\]. This is the case for any gram-negative pathogen of severe sepsis or septic shock \[[@CR24]\]. In the present study, the effect size was even greater, with a more than fivefold increase in the relative risk of receiving IET compared with non-MDR-AB. This suggests that clinicians should consider broad empiric coverage when AB is either suspected or identified by rapid testing.

In sepsis and pneumonia, it has been shown repeatedly that IET increases hospital mortality two- to fourfold and that escalation of treatment in response to culture results fails to alter this outcome \[[@CR4]--[@CR13]\]. Specific to AB sepsis and septic shock patients, Shorr et al. recently reported a significantly elevated risk of mortality associated with IET (risk ratio 1.42, 95 % CI 1.10--1.58, *p* = 0.015) \[[@CR14]\]. We confirm this observation in a cohort of patients with AB pneumonia or sepsis. However, this association has not always been found in studies of AB infection. While researchers in two additional cohort studies reported a two- to sixfold rise in hospital mortality in association with IET for AB, six other study groups failed to detect such an association \[[@CR25]--[@CR32]\]. Though it is not clear why such a well-recognized relationship would not exist specifically in the setting of AB, there are a number of potential reasons for this divergence. Some of the previous studies suffer from several methodological issues, such as small sample size, incomplete adjustment for or unmeasured confounders, and overadjusting for some factors that may be collinear.

Our study has a number of strengths and limitations. It included a large multicenter cohort representative of U.S. institutions and thus has broad generalizability. Though largely representative of U.S. institutions overall, the southern portion of the United States is overrepresented in the database. Although this made the study susceptible to bias, particularly selection bias, we dealt with it by setting a priori enrollment criteria and definitions for the main exposures and outcomes. Though some misclassification is possible, the main exposures (MDR-AB, IET) and outcomes (IET, hospital mortality) are minimally susceptible to misclassification. At the same time, in at least some of the identified cases, AB might have represented colonization rather than true infection. Additionally, the fact that fully one-third of all MDR-AB were isolates from cases defined as CA suggests that some misclassification may exist in this group; that is, it is possible that we were unable to identify these patients' exposure to the healthcare system with the variables available in the current database. Although confounding is a potential issue in observational studies, we attempted to eliminate this through regression analyses using a large number of potentially confounding variables. Nevertheless, the possibility of residual confounding remains.

Conclusions {#Sec10}
===========

In this largest representative multicenter study to date, although AB was a rare pathogen in CA or HCA pneumonia or sepsis, over 80 % of the AB isolates exhibited MDR. MDR increased the risk of receiving IET fivefold. In turn, IET was associated with increased risk of in-hospital mortality.

Key messages {#Sec11}
============

AB is a rare pathogen in community-acquired or healthcare-associated pneumonia or sepsis.Eighty percent of all AB in this population is MDR.MDR raises the risk of receiving inappropriate empiric therapy fivefold.Inappropriate empiric therapy increases the risk of hospital mortality.

Abbreviations {#Sec12}
=============
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